Trustiva
Tenofovir Disoproxil · Efavirenz · Emtricitabine
Intended to relieve retroviral multiplication to support immune CD4 count preservation and target viral replicative enzymes.
- Categories
- HIV Management · Antivirals
- Active ingredients
- Tenofovir Disoproxil · Efavirenz · Emtricitabine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 300mg + 600mg + 200mg
Prescription and consultation requirements for Trustiva vary by destination and are determined by the fulfilment partner.
Trustiva details
- Alternative names
- tenofovir, efavirenz, emtricitabine
- Therapeutic class
- Nucleoside Analog and Non-Nucleoside Reverse Transcriptase Inhibitor Combination
- Pharmacological class
- Antiretroviral Combination
- Minor side effects
- dizziness; headache; insomnia
- Moderate side effects
- vivid dreams; rash; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Hetero Healthcare
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Simvastatin; St. John's Wort
- Age restrictions
- Approved for adults weighing over thirty-five kilograms.
Contraindications
severe renal impairment; concurrent highly CYP3A4-dependent therapies; hepatic failure
Serious side effects
lactic acidosis, requires immediate medical attention; severe bone marrow suppression, requires immediate medical attention; suicidal ideation, requires immediate medical attention
Patient summary
intended to relieve retroviral multiplication to support immune CD4 count preservation and target viral replicative enzymes.
Mechanism of action
Efavirenz blocks reverse transcriptase non-competitively, while tenofovir and emtricitabine act as DNA chain terminators.
Pregnancy and breastfeeding
TGA Category D: Avoid in first trimester. Discontinue breastfeeding to prevent transmission.